-
公开(公告)号：US07700551B2
公开(公告)日：2010-04-20
申请号：US12215218
申请日：2008-06-25
申请人： Peter Turecek , Juergen Siekmann
发明人： Peter Turecek , Juergen Siekmann
CPC分类号： A61K47/61
摘要： The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.
摘要翻译： 本发明涉及Fmoc（9-芴基 - 甲氧基羰基）基聚合物共轭物。 这些缀合物可用于延长蛋白质和肽类药物的体内循环。
-
公开(公告)号：US20090176708A1
公开(公告)日：2009-07-09
申请号：US12339619
申请日：2008-12-19
IPC分类号： A61K38/36 , C07K14/745 , A61P7/04
CPC分类号： C12N9/644 , A61K38/00 , C12N9/96 , C12Y304/21022
摘要： The present invention discloses a chemically modified FIX, wherein the activation peptide region contains a covalently coupled water-soluble hydrophilic polymer.
摘要翻译： 本发明公开了一种化学修饰的FIX，其中活化肽区含有共价偶联的水溶性亲水性聚合物。
-
公开(公告)号：US20060045796A1
公开(公告)日：2006-03-02
申请号：US10924579
申请日：2004-08-24
申请人： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
发明人： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
CPC分类号： A61L2/10 , A23L3/26 , A23L3/28 , A61L2/0011 , A61L2/28 , G01N21/33 , H05B3/0052
摘要： The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
-
公开(公告)号：US20060003921A1
公开(公告)日：2006-01-05
申请号：US11218406
申请日：2005-09-02
IPC分类号： A61K38/37
CPC分类号： A61K38/37
摘要： Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
摘要翻译： 描述了一种用于治疗凝血障碍的药物制剂，其包含有效量的vWF前肽以及制备这种制剂的方法。
-
65.发明授权Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV 有权表现出von Willebrand因子（vWF）蛋白酶活性的组合物，其包含具有氨基酸序列AAGGILHLELLV的多肽链公开(公告)号：US06926894B2
公开(公告)日：2005-08-09
申请号：US09833328
申请日：2001-04-12
申请人： Bernhard Laemmle , Helena Elisabeth Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
发明人： Bernhard Laemmle , Helena Elisabeth Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
CPC分类号： A61K38/4886 , A61K38/00 , C07K14/755 , C07K16/36 , C12N9/6416 , C12N9/6489 , C12Y304/24087
摘要： The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV (SEQ ID NO: 1), vWF cleaving complexes and methods for their production.
摘要翻译： 本发明涉及分子量为180kD，170kD，160kD，120kD或110kD的VWF切割实体以及AAGGILHLELLV（SEQ ID NO：1）的N-末端氨基酸序列，vWF切割复合物和用于 他们的生产。
-
66.发明授权公开(公告)号：US06777390B1
公开(公告)日：2004-08-17
申请号：US09719945
申请日：2001-02-20
IPC分类号： A61K3800
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： Stable pharmaceutical preparations containing blood coagulation Factor VII is disclosed. The pharmaceutical preparations containing blood coagulation Factor VII are free of coagulation inhibitors and are stable over a wide range of environmental conditions. Also provided are blood coagulation Factor VII preparations having a minimum activity of 50 Units/mg of protein that contain less than 5% activated blood coagulation Factor VII (Factor VIIa). The blood coagulation Factor VII containing preparations may also contain other blood coagulation factors and are free from detectable transmissible human pathogens.
摘要翻译： 公开了含有凝血因子VII的稳定的药物制剂。 含有凝血因子VII的药物制剂不含凝血抑制剂，并且在宽范围的环境条件下是稳定的。 还提供具有最小活性为50单位/ mg蛋白质的含有少于5％的活化凝血因子VII（因子VIIa）的凝血因子Ⅶ制剂。 含有凝血因子Ⅶ的制剂还可含有其他凝血因子，并且不含可检测的可传播的人类病原体。
-
67.发明授权公开(公告)号：US09587249B2
公开(公告)日：2017-03-07
申请号：US12606884
申请日：2009-10-27
IPC分类号： A01K67/027 , C12N15/85
CPC分类号： A61K49/0008 , A01K67/027 , A01K67/0275 , A01K67/0276 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , A01K2267/0325 , A01K2267/0381 , C12N15/8509
摘要： The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
摘要翻译： 本发明涉及用于测试治疗凝血障碍的各种药剂的动物模型的开发。 更具体地，本发明涉及在各种小鼠品系中使用超大分子量多聚体维生素B因子（VWF）以诱导血小板减少性紫癜（TTP）样症状，用于开发TTP的小鼠模型。 本发明还提供了产生用于鉴定有效治疗TTP的生物活性化合物的动物疾病模型和筛选方法。
-
公开(公告)号：US08703429B2
公开(公告)日：2014-04-22
申请号：US12171934
申请日：2008-07-11
申请人： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
发明人： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
CPC分类号： A61K38/4886 , A61K38/00 , C07K14/755 , C07K16/36 , C12N9/6416 , C12N9/6489 , C12Y304/24087
摘要： The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
-
69.发明授权Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV 有权显示von Willebrand因子（vWF）蛋白酶活性的组合包含具有氨基酸序列AAGGILHLELLV的多肽链公开(公告)号：US08703426B2
公开(公告)日：2014-04-22
申请号：US12032553
申请日：2008-02-15
申请人： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
发明人： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
CPC分类号： A61K38/4886 , A61K38/00 , C07K14/755 , C07K16/36 , C12N9/6416 , C12N9/6489 , C12Y304/24087
摘要： The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
摘要翻译： 本发明涉及分子量为180kD，170kD，160kD，120kD或110kD的VWF切割实体以及AAGGILHLELLV的N-末端氨基酸序列，vWF切割复合物及其生产方法。
-
70.发明申请KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A SAMPLE OF A PATIENT'S BLOOD OR PLASMA 有权用于测量患者血液或血浆样本中样品的血小板生成的试剂盒公开(公告)号：US20130052672A1
公开(公告)日：2013-02-28
申请号：US13539154
申请日：2012-06-29
IPC分类号： G01N21/64
CPC分类号： A61K31/66 , C12Q1/56 , G01N33/86 , G01N2333/745
摘要： The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
摘要翻译： 本发明提供了一种用于测量患者血液或血浆样品或凝血因子样品中的凝血酶产生的试剂盒。 该试剂盒含有冻干组织因子/磷脂复合物和含有凝血酶底物和CaCl 2的冻干混合物。 本发明还提供了用于制备试剂盒的试剂的方法。 该试剂盒可以用于测量样品中凝血酶产生的方法，其中可以检测凝血酶产生动力学的变化，例如在将抑制剂旁路剂施用于已经开发出外源凝血因子的抑制剂的患者之后 作为因子VIII。
-
-
-
-
-
-
-
-
-
搜索结果
149 条记录 (耗时 0.036 秒)
